Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies.1 Icotrokinra also showed ...
Dellia Group ASA has been listed on Euronext Oslo Børs with an opening share price of NOK 135, corresponding to a market value of about NOK 649.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback